CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to PRAX

Phase 3

Development Phase

2

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
2mo
PRAXPDUFA
Phase 3

FDA PDUFA Date relutrigine (PRAX-562)

PRAX-562
Dec 27
Source
00%
Dec '26
PRAXPhase 3

PRAX-562 Phase 3 Est. Readout (EMERALD)

PRAX-562
Dec 2026~
CT.gov
00%
Competitive Landscape

0 competitors in SCN2A Encephalopathy

View Full Landscape
Drug Information

Target Indication

SCN2A Encephalopathy

Clinical Trial

NCT05818553

Last updated: 6/26/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.